1. "2024"
Formats
  1. Journal Article (2329)
  2. Meeting Abstract (1694)
  3. Review (589)
  4. Editorial (305)
  5. Book Section (98)
  6. Correspondence (92)
  7. Guidelines (90)
  8. Research Letter (89)
  9. Miscellaneous (55)
  10. Conference Paper (33)
  11. Book Whole (3)
Groups
  1. Department of Medicine (2141)
  2. Solid Tumor Oncology Division (1382)
  3. Sloan Kettering Institute Postdocs (1038)
  4. Surgery (984)
  5. Graduate Medical Education (883)
  6. GSK Faculty (868)

More Groups

People
  1. Eileen O'Reilly (75)
  2. Saad Usmani (75)
  3. Edward Christopher Dee (70)
  4. Nadeem Abu-Rustum (70)
  5. Alice Wei (69)
  6. T Peter Kingham (68)

More People

Years
  1. 2024 (5377)
Publications
  1. Journal of Clinical Oncology (521)
  2. International Journal of Radiation Oncology, Biology, Physics (186)
  3. Blood (161)
  4. Annals of Oncology (147)
  5. Annals of Surgical Oncology (131)
  6. Laboratory Investigation (91)

More Publications

Publishers
  1. Elsevier Inc. (784)
  2. American Society of Clinical Oncology (580)
  3. Nature Publishing Group (384)
  4. Springer (357)
  5. Oxford University Press (347)
  6. Elsevier Science, Inc. (256)

More Publishers

Results (5377)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase I trial of AVA6000, a fibroblast activation protein (FAP)-released, tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
    Meeting Abstract

    Twelves, C. J.; Banerji, U.; Tap, W. D.; Cook, N.; Evans, T. R. J.; Plummer, R.; Anthoney, A.; Plummer, C.; Dawson, R.; Loadman, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors
    Meeting Abstract

    Powles, T. B.; Bhatia, A. K.; Burtness, B.; Kogawa, T.; Nishina, T.; Nakayama, I.; Fountzilas, C.; Castillo, D. R.; McKean, M.; Meric-Bernstam, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF)
    Meeting Abstract

    Carneiro, B. A.; Rosen, E.; Fontana, E.; Lee, E. K.; Mettu, N. B.; Lheureux, S.; Plummer, R.; Silverman, I. M.; Schonhoft, J. D.; Yang, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in non-primary central nervous system (CNS) TRK fusion cancer
    Meeting Abstract

    Drilon, A. E.; Xu, R. H.; van Tilburg, C. M.; Doz, F.; Tan, D. S. W.; Lin, J. J.; Geoerger, B.; Zwaan, C. M.; Lassen, U. N.; Italiano, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib as first-line treatment for patients (pts) with TRK fusion cancer: An updated analysis
    Meeting Abstract

    Hong, D. S.; Xu, R. H.; Shen, L.; Dierselhuis, M. P.; Orbach, D.; McDermott, R. S.; Italiano, A.; Tahara, M.; Bernard-Gauthier, V.; Neu, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Park, W.; Kasi, A.; Spira, A. I.; Berlin, J. D.; Wang, J. S.; Herzberg, B.; Kuboki, Y.; Kitano, S.; Pelster, M.; Goldman, J. W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First clinical results from a phase I trial of PRT3789: A first-in-class intravenous SMARCA2 degrader, in patients with advanced solid tumors with a SMARCA4 mutation
    Meeting Abstract

    Guo, R.; Dowlati, A.; Dagogo-Jack, I.; Vibert, J.; Spira, A. I.; Moreno Garcia, V.; Punekar, S.; Calvo, E.; Sonpavde, G. P.; Awad, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary results from a phase I study of CFT1946, a novel BIDAC degrader in mutant BRAF V600 solid tumors
    Meeting Abstract

    Vieito, M.; McKean, M.; Spira, A. I.; Rosen, E.; Rodon, J.; Garcia, V. M.; Gambardella, V.; Saavedra, O.; Cousin, S.; Cassier, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC)
    Meeting Abstract

    George, M.; Frenel, J. S.; CorteĢs, J.; Schmidt, M.; Saenz, J. A. G.; Blau, S.; Abdulla, N. E.; Nishimura, M.; Sakai, H.; Babu, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save